Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Novo Nordisk’s blockbuster weight-loss drug cuts the risk of kidney disease-related events in diabetic patients by 24%, according to a new clinical trial conducted by the company.

Danish drug maker Novo Nordisk said on Thursday it would acquire Canadian company Inversago Pharma in a $1.07 billion deal including the development of an appetite regulator.

Novo Nordisk, which manufactures the fiercely popular weight-loss drug Wegovy, previously forecast weight loss of 25% for patients who take CagriSema. In another late-trial result published in ...